

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 October 2006 (12.10.2006)

PCT

(10) International Publication Number
WO 2006/108127 A2

- (51) International Patent Classification: Not classified
- (21) International Application Number:
PCT/US2006/012978
- (22) International Filing Date: 5 April 2006 (05.04.2006)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/668,780 6 April 2005 (06.04.2005) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/668,780 (CIP)
Filed on 6 April 2005 (06.04.2005)
- (71) Applicant (for all designated States except US): **THERAVANCE, INC.** [US/US]; 901 Gateway Boulevard, South San Francisco, California 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **FATHEREE, Paul R.** [US/US]; 921 Minnesota Street, San Francisco, California 94107 (US). **TURNER, S. Derek** [US/US]; 193b Warren Drive, San Francisco, California 94131 (US). **GOLDBLUM, Adam** [US/US]; 505 Molimo Drive, San Francisco, California 94127 (US). **CHAO, Robert** [US/US]; 1121 Doyle Circle, Santa Clara, California 95054 (US). **GENOV, Daniel** [US/US]; 888 O'farrell Street, Apt W405, San Francisco, California 94109 (US).
- (74) Agents: **HAGENAH, Jeffrey A.** et al.; THERAVANCE, INC., 901 Gateway Boulevard, South San Francisco, California 94080 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND

(57) Abstract: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5 HT₄ receptor activity, and processes useful for preparing such crystalline salt forms.

WO 2006/108127 A2